Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 14 April 2009, doi:10.1136/bmj.b1088
Cite this as: BMJ 2009;338:b1088
Steven P Cohen, associate professor1,2, Scott A Strassels, assistant professor 3, Leslie Foster, assistant professor4, John Marvel, assistant professor5, Kayode Williams, assistant professor5, Matthew Crooks, assistant professor5, Andrew Gross, pain management fellow6, Connie Kurihara, pain management center2, Cuong Nguyen, chief7, Necia Williams, chief8
1 Departments of Anesthesiology and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA, 2 Walter Reed Army Medical Center, Washington, DC, USA, 3 Division of Pharmacy Practice, University of Texas at Austin, Austin, TX, USA, 4 Department of Orthopedic Surgery, Walter Reed Army Medical Center, 5 Department of Anesthesiology, Johns Hopkins School of Medicine, 6 Department of Anesthesiology, Emory University School of Medicine, Atlanta, GA, USA, 7 Physical Medicine and Rehabilitation Service, Department of Surgery, Landstuhl Regional Medical Center, Landstuhl, Germany, 8 Integrated Anesthesia Services, Walter Reed Army Medical Center and National Naval Medical Center, Bethesda, MD
Correspondence to: S P Cohen, 550 North Broadway, Suite 301, Baltimore, MD 21029 scohen40{at}jhmi.edu
Design Multicentre double blind randomised controlled study.
Setting Three academic and military treatment facilities in the United States and Germany.
Participants 65 patients with a clinical diagnosis of greater trochanteric pain syndrome.
Interventions Injections of corticosteroid and local anaesthetic into the trochanteric bursa, using fluoroscopy (n=32) or landmarks (that is, "blind" injections; n=33) for guidance.
Main outcome measures Primary outcome measures: 0-10 numerical rating scale pain scores at rest and with activity at one month (positive categorical outcome predefined as
50% pain reduction either at rest or with activity, coupled with positive global perceived effect). Secondary outcome measures included Oswestry disability scores, SF-36 scores, reduction in drug use, and patients satisfaction.
Results No differences in outcomes occurred favouring either the fluoroscopy or blind treatment groups. One month after injection the average pain scores were 2.7 at rest and 5.0 with activity in the fluoroscopy group compared with 2.2 and 4.0 in the blind injection group. Three months after the injection, 15 (47%) patients in the blind group and 13 (41%) in the fluoroscopy group continued to have a positive outcome.
Conclusion Although using fluoroscopic guidance dramatically increases treatment costs for greater trochanteric pain syndrome, it does not necessarily improve outcomes.
Trial registration Clinical trials NCT00480675 [ClinicalTrials.gov]
© Cohen et al 2009
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses